Cellular fatty acid synthase is required for late stages of HIV-1 replication
Authors:
- Manjusha M. KulkarniMKManjusha M. Kulkarni
- Annette N. RatcliffARAnnette N. Ratcliff
- Menakshi BhatMBMenakshi Bhat
- Yazan AlwarawrahYAYazan Alwarawrah
- Philip HughesPHPhilip Hughes
- Jesus ArcosJAJesus Arcos
- David LoiselleDLDavid Loiselle
- Jordi B. TorrellesJTJordi B. Torrelles
- Nicholas T. FunderburgNFNicholas T. Funderburg
- Timothy A. HaysteadTHTimothy A. Haystead
- Jesse J. KwiekJKJesse J. Kwiek
Open Access
- 29 September 2017
- journal article
- research article
- Published by Springer Nature in Retrovirology
- Vol. 14 (1) , 45
Abstract
Like all viruses, HIV-1 relies on host systems to replicate. The human purinome consists of approximately two thousand proteins that bind and use purines such as ATP, NADH, and NADPH. By virtue of their purine binding pockets, purinome proteins are highly druggable, and many existing drugs target purine-using enzymes. Leveraging a protein affinity media that uses the purine-binding pocket to capture the entire purinome, we sought to define purine-binding proteins regulated by HIV-1 infection. Using purinome capture media, we observed that HIV-1 infection increases intracellular levels of fatty acid synthase (FASN), a NADPH-using enzyme critical to the synthesis of de novo fatty acids. siRNA mediated knockdown of FASN reduced HIV-1 particle production by 80%, and treatment of tissue culture cells or primary PBMCs with Fasnall, a newly described selective FASN inhibitor, reduced HIV-1 virion production by 90% (EC50 = 213 nM). Despite the requirement of FASN for nascent virion production, FASN activity was not required for intracellular Gag protein production, indicating that FASN dependent de novo fatty acid biosynthesis contributes to a late step of HIV-1 replication. Here we show that HIV-1 replication both increases FASN levels and requires host FASN activity. We also report that Fasnall, a novel FASN inhibitor that demonstrates anti-tumor activity in vivo, is a potent and efficacious antiviral, blocking HIV-1 replication in both tissue culture and primary cell models of HIV-1 replication. In adults, most fatty acids are obtained exogenously from the diet, thus making FASN a plausible candidate for pharmacological intervention. In conclusion, we hypothesize that FASN is a novel host dependency factor and that inhibition of FASN activity has the potential to be exploited as an antiretroviral strategy.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (AI090644)
- National Heart, Lung, and Blood Institute (108743, 126563)
- Pelotonia
This publication has 57 references indexed in Scilit:
- A genome-wide CRISPR screen identifies a restricted set of HIV host dependency factorsNature Genetics, 2016
- Uncovering the global host cell requirements for influenza virus replication via RNAi screeningMicrobes and Infection, 2011
- Host Cell Factors in HIV Replication: Meta-Analysis of Genome-Wide StudiesPLOS Pathogens, 2009
- Discovery of insect and human dengue virus host factorsNature, 2009
- A Functional Genomic Screen Identifies Cellular Cofactors of Hepatitis C Virus ReplicationCell Host & Microbe, 2009
- Genome-Scale RNAi Screen for Host Factors Required for HIV ReplicationCell Host & Microbe, 2008
- Knockdown Screens to Knockout HIV-1Cell, 2008
- Global Analysis of Host-Pathogen Interactions that Regulate Early-Stage HIV-1 ReplicationCell, 2008
- RNA interference screen for human genes associated with West Nile virus infectionNature, 2008
- Identification of Host Proteins Required for HIV Infection Through a Functional Genomic ScreenScience, 2008